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PCoronary Artery Disease
Circulating Osteoprotegerin
Levels and Long-Term Prognosis in
Patients With Acute Coronary Syndromes
Torbjørn Omland, MD, PHD, MPH,*† Thor Ueland, PHD,‡ Anna M. Jansson, MD,§
Anita Persson, MSC, Thomas Karlsson, MSC,¶ Camilla Smith, MD,‡ Johan Herlitz, MD, PHD,¶
Pål Aukrust, MD, PHD,‡ Marianne Hartford, MD, PHD,¶# Kenneth Caidahl, MD, PHD§
Lørenskog and Oslo, Norway; and Stockholm, Göteborg, and Mölndal, Sweden
Objectives This study was designed to assess the association between osteoprotegerin (OPG) levels on admission and long-
term prognosis in patients with acute coronary syndromes (ACS).
Background Osteoprotegerin, a member of the tumor necrosis factor receptor superfamily, has pleiotropic effects on bone
metabolism, endocrine function, and the immune system.
Methods Serum samples for OPG analysis were obtained within 24 h of admission in 897 ACS patients (median age 66
years, 71% men) and related to the incidence of death, heart failure (HF) hospitalizations, myocardial infarction
(MI), and stroke.
Results A total of 261 patients died during a median follow-up of 89 months. The baseline OPG concentration was
strongly associated with increased long-term mortality (hazard ratio [HR] for HR per 1 SD increase in logarithmi-
cally transformed OPG level 1.7 [range 1.5 to 1.9] p  0.0001) and HF hospitalizations (HR 2.0 [range 1.6 to
2.5]; p  0.0001) but weaker with recurrent MI (HR 1.3 [range 1.0 to 1.5]; p  0.02) and not with stroke (HR
1.2 [range 0.9 to 1.6]; p  0.35). After adjustment for conventional risk markers, including troponin I, C-reactive
protein (CRP), B-type natriuretic peptide (BNP), and ejection fraction, the association remained significant for
mortality (HR 1.4 [range 1.2 to 1.7]; p  0.0001) and HF hospitalization (HR 1.6 [range 1.2 to 2.1]; p  0.0002),
but not recurrent MI. By comparison of the area under the receiver-operating characteristics curves, OPG performed
similarly to BNP and ejection fraction and significantly better than CRP and troponin I as a predictor of death.
Conclusions Serum OPG is strongly predictive of long-term mortality and HF development in patients with ACS, independent
of conventional risk markers. (J Am Coll Cardiol 2008;51:627–33) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.058o
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icute coronary syndromes (ACS) encompass a range of
linical manifestations of the rupture or erosion of a coro-
ary atherosclerotic plaque (1). Depending on whether the
cute plaque rupture results in subtotal or transient or
ermanent total occlusion of the diseased vessel, as well as
rom the *Department of Medicine, Akershus University Hospital, Lørenskog,
orway; †Faculty of Medicine, University of Oslo, Oslo, Norway; ‡Research Institute
or Internal Medicine, Rikshospitalet, Oslo, Norway; §Department of Molecular
edicine and Surgery, Karolinska Institutet and Karolinska University Hospital,
tockholm, Sweden; Department of Clinical Physiology, Sahlgrenska University
ospital, Göteborg, Sweden; ¶Department of Cardiology, Sahlgrenska University
ospital, Göteborg, Sweden; and #AstraZeneca R&D, Mölndal, Sweden. This study
as supported by the Swedish Research Council (14231), the Swedish Heart and
ung Foundation, the Västra Götaland Region, the Vardal Foundation, Göteborg
niversity, and the Göteborg Medical Society. Drs. Aukrust and Ueland are listed as
o-inventors on a pending patent application on the use of osteoprotegerin as a
rognostic marker in cardiovascular disorders.p
Manuscript received July 3, 2007; revised manuscript received September 17, 2007,
ccepted September 23, 2007.n the size and degree of collateral circulation to the
eopardized myocardium, the clinical presentation may vary
rom unstable angina pectoris to non–ST-segment elevation
yocardial infarction (MI) or ST-segment elevation MI.
he prognosis of patients with ACS varies widely, and a
umber of clinical, electrocardiographic, and biochemical
arkers have been shown to predict adverse short-term and
ong-term outcome. Although several classes of biomarkers,
ncluding markers of ischemia, inflammation, hemodynamic
tress, accelerated atherosclerosis, and myocardial damage,
ave been associated with prognosis in acute coronary
yndromes (2), cardiac-specific troponins are currently the
nly markers uniformly used for diagnosis and risk stratifi-
ation (3).
An excessive inflammatory response to various forms of
njurious stimuli to the arterial wall is characteristic for the
rocess of atherosclerosis and plaque destabilization (4,5),
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Osteoprotegerin and Prognosis in ACS February 12, 2008:627–33involving various inflammatory
mediators including adhesion
molecules, chemokines, and cy-
tokines (5,6). Osteoprotegerin
(OPG) is a soluble member of
the tumor necrosis factor (TNF)
receptor superfamily with pleio-
tropic effects on bone metabo-
lism, endocrine function, and the
immune system (7). Osteoprote-
gerin inhibits osteoclastogenesis
by binding the receptor activator
of nuclear factor-B ligand
(RANKL), acting as a decoy re-
ceptor to competitively inhibit
RANKL interaction with its re-
ceptor, RANK (8). Recently, the
OPG/RANKL/RANK axis has
been implicated in various in-
flammatory responses and has
also been linked to atherogenesis.
steoprotegerin can be detected in atherosclerotic lesions
9,10), and in humans, elevated circulating OPG concen-
rations have been associated with aortic plaque (11), as well
s with increased prevalence and severity of coronary artery
isease (12–15), cerebrovascular disease (14), and peripheral
ascular disease (16). Circulating OPG levels are increased
oth in patients with unstable angina (10) and ST-segment
levation MI (17). Limited prognostic data are currently
vailable, but in a recent population-based study (14),
levated circulating OPG levels were predictive of future
ardiovascular events. Moreover, in a small-scale study with
o adjustment for objective measures of ventricular func-
ion, we have recently shown (18) that OPG levels are
redictive of survival in patients with post-infarction heart
ailure (HF).
On the basis of this information, we hypothesized that
PG may be independently predictive of long-term prog-
osis across the spectrum of ACS. To test this hypothesis,
e measured OPG in serum samples obtained from a large
eries of patients admitted to a Scandinavian teaching
ospital with ACS. Because the presence of both systolic
eft ventricular dysfunction and clinical HF also are associ-
ted with activation of OPG (19,20), we were particularly
nterested in assessing the prognostic value of OPG after
djustment for left ventricular ejection fraction (LVEF) and
fter adjustment for the most widely used contemporary
ardiovascular biomarkers: troponin I, C-reactive protein
CRP), and B-type natriuretic peptide (BNP).
ethods
tudy design. Patients with ACS, defined as a diagnosis of
nstable angina, non–ST-segment elevation MI, or ST-
egment elevation MI, admitted to the coronary care unit of
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
BNP  B-type natriuretic
peptide
CI  confidence interval
CRP  C-reactive protein
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
OPG  osteoprotegerin
RANK  receptor activator
of nuclear factor-B
RANKL  receptor
activator of nuclear factor-
B ligandhe Sahlgrenska University Hospital, Göteborg, Sweden, puring the period November 30, 1996, to March 31, 2001,
ere eligible for inclusion in a prospective risk stratification
rogram, PRACSIS (Prognosis and Risk in Acute Coro-
ary Syndrome in Sweden) (21). During this period, a total
f 1,753 patients were screened, out of whom 897 patients
51%) were included in the current study. The main
xclusion criteria were age 18 or 80 years, non-CAD
ssociated with an expected life expectancy 1 year, resi-
ence outside the city of Göteborg, unwillingness to par-
icipate or to provide blood samples, and prior admission
esulting in inclusion in the study. The primary outcome
easure was all-cause mortality from the time of inclusion
n the study to December 31, 2006. Survival confirmation
nd date of death were obtained from the Swedish National
opulation Registry. Five patients, who emigrated from
weden, were lost to follow-up and censored alive at the day
f emigration. Secondary outcome measures were the inci-
ence of acute MI (International Statistical Classification of
isease, Ninth Revision [ICD-9] code 410 or ICD-10 code
21 or I22), congestive HF (ICD-9 code 428 or ICD-10
ode I50), and stroke (ICD-9 codes 431, 432, 433, or 436
r ICD-10 codes I61, I62, I63, or I64) from the time of
nclusion in the study to January 2003, as obtained from the
wedish Hospital Discharge Registry. For quality control
urposes, morbidity data from the Registry was checked
gainst information in the patients’ medical records by a
ardiologist (M. H.) blinded to biomarker results. Because
f a time lag in the publication of data from the Swedish
ospital Discharge Registry and the manual quality control,
orbidity data are available only until January 2003. Pa-
ients were prospectively classified according to maximum
illip class on admission and during the index hospitaliza-
ion. Electrocardiographic findings on admission were clas-
ified according to the presence or absence of ST-segment
levation and ST-segment depression. On the basis of
ospital records and personal interviews, patients were
lassified as having or not having a history of MI, angina
ectoris, chronic HF, diabetes mellitus, or arterial hyper-
ension. The study protocol was approved by the Regional
thics Committee before the initiation of the study. In-
ormed consent was obtained from all participating patients.
lood sampling procedures and echocardiography. Pe-
ipheral venous blood was obtained within 24 h of admis-
ion by direct venipuncture of an antecubital vein after the
atients had been supine for 30 min. Blood samples for
PG determination were drawn into sterile serum tubes
nd centrifuged within 1 h. Blood samples for determina-
ion of troponin I, CRP, and BNP were drawn into
yrogen-free tubes with ethylenediaminetetra-acetic acid
EDTA) as anticoagulant, immediately immersed in ice
ater and centrifuged at 2,000 g for 10 min within 1 h.
ll plasma and serum samples were stored at 70 °C and
hawed only once before analyses. Echocardiographic
nvestigation was performed by an experienced investiga-
or within 5 days of hospital admission as described
reviously (22).
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February 12, 2008:627–33 Osteoprotegerin and Prognosis in ACSiochemical analysis. Serum OPG was quantified in du-
licate by an enzyme immunoassay using commercially
vailable matched antibodies (R&D Systems, Minneapolis,
innesota). The intra- and interassay coefficients of varia-
ion were 3.6% and 10.6%, respectively. The coefficient of
ariation percentage was evaluated at the median concen-
ration observed in normal subjects. The sensitivity, defined
s the mean  3 SD of the 0 standard, was calculated to be
5 pg/ml (18). Creatine kinase (CK)-MB fraction in serum
as measured on a modular platform (Roche Diagnostics,
annheim, Germany). The BNP, CRP, and troponin I
ere measured using immunofluorescent assays calibrated
ith spiked plasma (Biosite Inc., San Diego, California).
ach sample was tested in duplicate. Samples for CRP
nalyses were diluted (factor 1600) to get the concentration
nto the measurable range. The minimal detectable concen-
ration upper range was 5 to 1,300 pg/ml for BNP, 0.05 to
0 g/l for troponin I, and 0.3 to 100 mg/l for CRP.
reatinine and total cholesterol concentrations in serum
ere determined by routine laboratory methods. Glomeru-
ar filtration rate in ml/min was estimated using the
ockcroft-Gault formula (140  age)  weight (kg)/serum
reatinine [mol/l]) multiplied by a constant of 1.23 in men
nd 1.04 in women.
tatistical analysis. Categorical variables are reported as
roportions and continuous variables as median values with
nterquartile ranges (25th to 75th percentile) or mean 
D. The association between OPG and baseline demo-
raphic variables and cardiovascular risk factors was tested
y the Mann-Whitney U test (comparing subjects with and
ithout a specific characteristic) and Spearman rank corre-
ation statistics (for testing of the association between
ontinuous variables and OPG). Accordingly, individual
PG values (not the median of each OPG quartile) were
sed for calculation of p values in Table 1.
To visualize the relationship between OPG quartiles and
ong-term prognosis, Kaplan-Meier plots were generated,
nd the log-rank test was used for the comparison of the
esulting curves.
Cox proportional hazards regression analyses were used
o calculate the crude and adjusted risk estimates associated
ith a 1-SD increase in logarithmically transformed OPG
evels for the end points mortality from all causes and the
rst hospitalization due to MI, stroke, or HF, respectively.
n the multivariable analyses, we adjusted for potential
onfounders deemed to be clinically relevant. Because of a
kewed distribution of data, the following continuous vari-
bles were logarithmically transformed: OPG, CRP, tropo-
in I, BNP, CK-MB, estimated glomerular filtration rate,
nd heart rate. With the exception of CK-MB and esti-
ated glomerular filtration rate, logarithmic transformation
esulted in reduced skewness of these variables. To assess
ny nonlinear association with outcome, we also examined
he association between OPG quartiles and the specific end
oints. The multivariable models included the following
ovariates: age, gender, index diagnosis, smoking status, [rior MI, diabetes, hypertension, congestive HF, Killip class
dichotomous, i.e., Killip class 1 vs. Killip class 2, 3, and 4),
stimated glomerular filtration rate, heart rate, peak CK-
B, troponin I, CRP, BNP, and LVEF. Hazard ratios
HR) are given with 95% confidence intervals.
The relative prognostic value of troponin I, CRP, BNP,
r LVEF versus OPG was assessed by comparing areas
nder receiver-operating characteristics curves using the
inimal common follow-up time of 69 months. All prob-
bility values are 2-tailed and were considered significant
hen 0.05. All statistical analyses were performed by
sing SAS version 9.1 (SAS Institute, Cary, North Carolina).
esults
haracteristics at baseline. The characteristics of patients
t baseline according to OPG quartile are presented in
able 1. In total, 897 patients (median age 66 years,
nterquartile range 58 to 73, 71% men) had OPG values
btained within 24 h of admission. Examination of strata
ased on time from symptom onset to blood collection did
ot reveal any time-dependent differences in OPG concen-
rations (12 h vs. 12 to 24 h vs. 24 h: 3,336 vs. 3,061 vs.
,209 pg/ml; p  0.79). Patients with higher OPG levels
ere more likely to be older; to have lower body mass index;
o be non-smokers; and to have a medical history of
ongestive HF, diabetes mellitus, or hypertension. An index
iagnosis of ST-segment elevation MI was associated with
igher OPG levels, and, consequently, an index diagnosis of
nstable angina was associated with lower OPG levels.
ccordingly, higher OPG levels were associated with in-
reased likelihood of ST-segment elevation and pathologi-
al Q waves on the electrocardiogram; increased concentra-
ions of the biochemical markers of myocardial necrosis,
uch as troponin I and creatine kinase-MB fraction; and
ncreased use of primary percutaneous coronary intervention
nd thrombolytic agents. Furthermore, patients with higher
PG levels were more likely to present with arterial
ypotension or clinical signs of HF, to be users of diuretics
nd angiotensin-converting enzyme inhibitors or angioten-
in receptor blockers, and to have impaired left ventricular
ystolic function as assessed by echocardiography. More-
ver, higher OPG levels were associated with increased
evels of BNP and CRP and with decreased renal function,
s expressed by estimated glomerular filtration rate. The
orrelations between OPG and other circulating biomarkers
ere modest, but highly significant (BNP: r  0.34; CRP:
 0.29; troponin I: r  0.20).
steoprotegerin and long-term mortality. During a me-
ian follow-up of 89 months (interquartile range 75 to 105)
onths, 261 patients died. The concentration of OPG at
aseline was closely associated with long-term all-cause
ortality (Fig. 1). By univariable analysis, the HR associ-
ted with a 1-SD increase in logarithmically transformed
PG levels at baseline was 1.7 (95% confidence intervalCI] 1.5 to 1.9); p  0.0001). When comparing the fourth
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Osteoprotegerin and Prognosis in ACS February 12, 2008:627–33ersus first quartile of OPG concentrations, the HR was 4.2
range 2.8 to 6.3), p  0.0001. After adjustment for age,
ender, index diagnosis, smoking status, prior MI, diabetes,
ypertension, HF, Killip class, estimated glomerular filtra-
ion rate, heart rate, peak CK-MB, troponin I, CRP, and
NP, the HR was 1.4 (range 1.2 to 1.6); p  0.0003
Table 2). The relationship remained significant in patients
n Killip class I (HR 1.3 [range 1.1 to 1.5]; p  0.002) and
egardless of index diagnosis (ST-elevation MI [n  388]:
R 1.3 [range 1.0 to 1.6]; p  0.02; non–ST-segment
levation ACS [n  509]: HR 1.4 [range 1.1 to 1.7]; p 
.003; unstable angina [n  198]: HR 1.7 [range 1.2 to
.4]; p  0.005). Osteoprotegerin was a strong and inde-
endent prognostic indicator in the subgroup of patients in
haracteristics at Baseline
Table 1 Characteristics at Baseline
OPG <2,316
(n  225)
OPG
(
Age (yrs) 59  10
Women (%) 25
Previous myocardial infarction (%) 23
Previous angina (%) 41
Previous chronic heart failure (%) 4
Previous diabetes (%) 13
Previous hypertension (%) 32
Previous hypercholesterolemia (%) 32
Current smoker (%) (17 missing) 39
ST-segment elevation MI (%) 33
Non–ST-segment elevation MI (%) 36
Unstable angina (%) 31
ST-segment elevation on admission (%) 29
ST-segment depression on admission (%) 12
Q-wave on admission (%) 8
Systolic blood pressure 100 mm Hg (%) 2
Heart rate (beats/min) 74 (60, 86) 72
Creatine kinase-MB max (g/l) 43 (6, 129) 42
Troponin I (g/l) 2.39 (0.07, 9.90) 3.58
B-type natriuretic peptide (pg/ml) 101 (52, 211) 196
C-reactive protein (mg/l) 9.2 (4.3, 21.0) 12.2
Glomerular filtration rate (mol/l)
(14 missing)
81 (64, 95) 64
Body mass index (kg/m2) (26 missing) 27 (24, 29) 26
Killip class II to IV on admission (%) 2
Max Killip class II to IV (%) 6
Thrombolysis/primary PCI (%) 27
Other PCI or CABG during hosp. (%) 34
LVEF (%) (173 missing) 59 (51, 63) 55
Beta-blocker (%) 28
ACEI/ARB (%) 11
Lipid-lowering drugs (%) 16
Aspirin (%) 29
Calcium channel blocker (%) 13
Diuretics (%) 8
alues given as percentage, mean  SD, or median (25th, 75th percentile). *Actual osteoprotege
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; CABG 
PG  osteoprotegerin (pg/ml); PCI  percutaneous coronary intervention.hom echocardiographically determined LVEF were avail- fble and adjusted for together with a number of clinical
ariables (n  724; HR 1.4 [range 1.2 to 1.6], p  0.0001).
Comparison of the overall prognostic merit of OPG
ersus troponin I, CRP, BNP, and LVEF as assessed by the
rea under the receiver-operating characteristics curve
howed that OPG (area: 0.68 [95% CI 0.64 to 0.73])
rovided significantly better prognostic information than
roponin I (area 0.55 [95% CI 0.50 to 0.60] p  0.001) and
RP (area 0.59 [95% CI 0.54 to 0.63], p  0.002) and
imilar information as BNP (area 0.70 [95% CI 0.66 to
.74]; p  0.28) and LVEF (area 0.71 [95% CI 0.66 to
.76]; p  0.09). However, the addition of OPG only
arginally, and not significantly, improved the overall
redictive ability of a multivariable model consisting of the
–3,171
24)
OPG 3,172–4,540
(n  224)
OPG >4,540
(n  224) p Value*
9 67  9 69  8 0.0001
30 33 0.05
20 21 0.71
39 48 0.30
10 9 0.009
21 22 0.003
44 48 0.0006
27 23 0.01
26 30 0.02
45 55 0.0001
37 31 0.34
18 14 0.0001
43 50 0.0001
13 12 0.61
17 17 0.0001
2 6 0.03
6) 70 (60, 85) 78 (62, 90) 0.12
3) 77 (16, 226) 97 (22, 264) 0.0001
, 13.88) 5.96 (0.59, 22.16) 7.93 (0.91, 20.84) 0.0001
332) 208 (104, 410) 278 (150, 552) 0.0001
7.0) 16.6 (6.8, 56.6) 26.0 (10.8, 69.9) 0.0001
0) 63 (51, 77) 57 (45, 68) 0.0001
8) 26 (23, 29) 25 (23, 28) 0.0002
7 8 0.002
21 32 0.0001
33 44 0.0001
29 21 0.002
2) 52 (44, 60) 50 (42, 59) 0.0001
35 32 0.40
14 19 0.02
12 12 0.08
30 30 0.99
15 15 0.42
14 15 0.005
e used in p value calculations.
ry artery bypass grafting; LVEF  left ventricular ejection fraction; MI  myocardial infarction;2,317
n  2
65 
29
22
42
8
12
39
33
35
40
35
25
36
11
8
2
(60, 8
(7, 15
(0.22
(101,
(4.0, 2
(55, 8
(24, 2
5
10
33
27
(45, 6
37
16
17
33
14
11
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coronaollowing variables: age, gender, index diagnosis, smoking
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eart rate, Killip class (I) on admission, estimated glo-
erular filtration rate, peak CK-MB, and troponin I (area
ithout OPG 0.797 [95% CI 0.760 to 0.830] vs. area with
PG: 0.805 [95% CI 0.768 to 0.838]; p  0.38).
steprotegerin and cardiovascular events. During
ollow-up, 107 patients were hospitalized with a main
iagnosis of MI, 85 patients were hospitalized with a main
iagnosis of HF, and 43 patients were hospitalized with
main diagnosis of stroke. By univariable analyses, the
aseline OPG concentration was strongly associated with
he incidence of HF hospitalizations (HR per 1-SD increase
n logarithmically transformed OPG level 2.0 [range 1.6 to
.5]; p  0.0001) but weaker with the incidence of
ecurrent MI (HR 1.3 [range 1.0 to 1.5]; p  0.02) and
ot with stroke (HR 1.2 [range 0.9 to 1.6]; p  0.35).
Figure 1 Osteoprotegerin and Long-Term Mortality
Association between osteoprotegerin
levels by quartiles and long-term mortality.
Associations Between Osteoprotegerin Concentand Events During Follow-Up in Acute Coronary
Table 2 Associations Between Osteoprotegand Events During Follow-Up in Acu
HR (9
Complete cohort (n  897)
Mortality 1.7 (1
Heart failure 2.0 (1
Recurrent MI 1.3 (1
Stroke 1.2 (0
Cohort with echocardiographically
determined ejection fraction (n  724)
Mortality 1.7 (1
Heart failure 1.9 (1
Recurrent MI 1.2 (1
Stroke 1.1 (0
*Adjusted for age, gender, index diagnosis, smoking status, prior myoc
Killip class (I) on admission, estimated glomerular filtration rate, pea
and ejection fraction.
HR  hazard ratio per 1-SD pg/ml increase in the natural logarithm of osthe association between OPG quartiles and the incidence
f HF hospitalizations is depicted in Figure 2. Using the
rst quartile as the reference, an OPG level in the fourth
uartile was associated with a more than 7-fold increase in
he risk of HF hospitalizations (HR 7.4 [95% CI 3.1 to
7.5]; p  0.0001). After adjustment for conventional risk
actors, OPG remained independently associated with the
ncidence of HF hospitalizations (HR per 1-SD increase in
ogarithmically transformed OPG level 1.6 [range 1.2 to
.1]; p  0.0002) but not to the incidence of recurrent MI
HR 1.0 [range 0.8 to 1.3]; p  0.70) (Table 2). After
urther adjustment for LVEF, the association between
PG and the incidence of HF hospitalizations remained
ignificant (HR 1.6 [range 1.2 to 2.1]; p 0.001) (Table 2).
espite a low number of end points (HF: n  19, recurrent
I: n  20), the same pattern was evident in the subgroup
f patients with unstable angina (HF: HR 2.4 [range 1.2 to
.8]; p  0.02; recurrent MI: HR 1.0 [range 0.5 to 1.7];
 0.92).
iscussion
he salient new information obtained from the current
tudy is that serum levels of OPG are strongly related to
ong-term mortality and the incidence of HF hospitaliza-
ions across the spectrum of ACS. These associations were
ttenuated but still highly significant after adjustment for
onventional risk factors as well as LVEF and multiple
ontemporary cardiovascular biomarkers (i.e., troponin I,
RP, and BNP) in multivariable analyses. In contrast to the
trong association with the incident HF, secondary analyses
howed that the association between OPG levels and MI,
lthough significant by univariable analysis, was no longer
ignificant after adjustment for potential confounders.
hese findings add important information to our knowledge
f the prognostic value of OPG in patients with cardiac
isease and are compatible with the theory that OPG levels
nsromes
oncentrations
ronary Syndromes
adjusted Adjusted*
) p Value HR (95% CI) p Value
) 0.0001 1.3 (1.1–1.5) 0.0003
) 0.0001 1.6 (1.2–2.1) 0.0002
) 0.02 1.0 (0.8–1.3) 0.70
) 0.35 0.9 (0.6–1.3) 0.61
) 0.0001 1.4 (1.2–1.7) 0.0001
) 0.0001 1.6 (1.2–2.1) 0.001
) 0.06 1.1 (0.8–1.4) 0.61
) 0.55 0.8 (0.6–1.2) 0.36
nfarction, diabetes, hypertension, congestive heart failure, heart rate,
ne kinase-MB, troponin I, B-type natriuretic peptide, C-reactive protein,ratioSynd
erin C
te Co
Un
5% CI
.5–1.9
.6–2.5
.0–1.5
.9–1.6
.5–2.0
.5–2.3
.0–1.5
.8–1.5
ardial i
k creatieoprotegerin; MI  myocardial infarction.
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Osteoprotegerin and Prognosis in ACS February 12, 2008:627–33o not exclusively reflect myocardial injury and subsequent
eft ventricular dysfunction in patients with ACS, but may
e an independent pathophysiological factor of potential
mportance for the progression of HF.
As both atherosclerosis and myocardial failure are asso-
iated with increased OPG levels (10,18), both these factors
ay contribute to an association of OPG with outcome in
atients with ACS. Demonstration of an independent
ssociation between OPG levels at baseline and the inci-
ence of hospitalizations for HF strongly suggests that
PG’s ability to predict mortality can be explained, at least
artially, by its prediction of HF development. Recent
tudies suggest that the cardiovascular system may be an
mportant contributor to circulating OPG levels. We have
ecently shown (20) strong OPG immunostaining within
he failing myocardium, and it is possible that the ability of
PG levels to predict development of HF may reflect the
ontribution of the myocardium itself to the circulating
PG levels.
The OPG/RANKL/RANK axis is known to play a role
n modulating immune function, including both innate and
daptive immune responses. Accordingly, these factors have
een shown to enhance activation of T-cells and dendritic
ells and to promote B-cell maturation and antibody re-
ponses (23) and have recently been found (10) to induce
atrix degradation and inflammation in ACS. Moreover,
e have previously shown that both experimental and
linical HF is associated with increased expression of the
PG/RANKL/RANK axis (20), and activation of this
ystem seems not only to be a marker of development of
F, but also a mediator in this process, at least partly by
romoting matrix degrading, inflammation, and ventricular
emodeling (20). Because OPG circulates at much higher
evels than RANKL, it may be a more stable overall measure
Figure 2 Osteoprotegerin and Heart Failure Hospitalization
Association between osteoprotegerin levels
by quartiles and the incidence of heart failure hospitalizations.f RANKL/RANK activity. The ability of OPG to reflect tANKL/RANK activity, a potential important mediator in
eft ventricular remodeling and a more general marker of
nflammation, could contribute to its prognostic impact.
In our study, OPG performed better than the prototyp-
cal inflammatory biomarker CRP as a predictor of death.
his observation, in combination with the strong associa-
ion between OPG and HF, suggests that OPG should not
e regarded exclusively as an unspecific marker of inflam-
ation. On the basis of our previous findings of strong
mmunostaining for OPG in the failing heart (20), it is
empting to speculate that OPG reflects the degree of
yocardial damage more directly than CRP.
Atherosclerosis is characterized by persistent inflamma-
ion in the vascular wall (24). Mineral deposition and
rterial calcification are other common features of the
therosclerotic process, and endochondral bone formation
as been suggested (25) as potential pathophysiological
echanisms of coronary calcification. Accordingly, several
one matrix-associated regulatory proteins, including OPG
nd RANKL, have been shown to be localized within
uman atherosclerotic plaques and at sites of arterial calci-
cation (9,10). However, the lack of an independent asso-
iation with acute atherosclerotic events (i.e., MI and
troke) does not favor the hypothesis that OPG plays an
mportant role in the pathogenesis of plaque destabilization.
The potential therapeutic consequences of our findings
re unclear. However, as OPG appears to predict HF
evelopment and not ischemic events, it is tempting to
peculate that OPG can be used to target ACS patients
ho may receive particular benefit from interventions
nown to delay or prevent HF development, such as
ngiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers.
trengths and limitations. The prospective design, large
ample size, long duration of follow-up, high number of
ost of the end points, and echocardiographic information
oncerning left ventricular systolic function in a consider-
ble proportion of patients are all important strengths of the
urrent single-center study. Limitations include the rela-
ively high proportion of screened patients that were not
ncluded in the study and the modest number of stroke
vents. All-cause mortality was used as a main outcome
easure in the current study. Data on cardiovascular mor-
ality would have been preferable, as this would have ruled
ut the possibility that the relation between OPG and
ortality could be partially ascribed to an unspecific asso-
iation between inflammation and non-cardiovascular dis-
ase. Accordingly, future studies should address the associ-
tion between OPG and cardiovascular mortality. The
nalytical performance and sensitivity of the troponin assay
sed in the current study are not optimal. Moreover, the use
f single rather than serial measurements of troponin does
ot mirror clinical practice, and both these factors may tend
o overstate the independent prognostic value of a new
arker. In addition, the study does not provide an answer tohe question whether OPG plays a pathophysiological role
o
d
C
T
s
t
t
o
o
B
p
e
d
t
A
T
a
a
w
C
H
s
R
D
a
S
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
633JACC Vol. 51, No. 6, 2008 Omland et al.
February 12, 2008:627–33 Osteoprotegerin and Prognosis in ACSr is merely a marker of severity of atherosclerosis and/or
egree of ventricular dysfunction.
onclusions
he current study documents that serum OPG levels are
trongly predictive of long-term mortality and HF hospi-
alizations in patients with ACS independently of conven-
ional risk markers. Notably, the prognostic information
btained from OPG in ACS appears to be of the same order
f magnitude as obtained from determination of LVEF and
NP, currently considered to be 2 of the most powerful
rognostic indicators in patients with ACS. To further
lucidate the role that OPG plays in atherosclerosis, plaque
estabilization and myocardial failure should be the objec-
ives of future investigations.
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